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Letters to the Editor
Autosomal  recessive  polycystic  kidney disease  diagnosed  in
a 39-year-old  woman  with  kidney  failure  and  crampsPoliquistosis  renal  autosómica  recesiva  diagnosticada  en  mujer  de
s
kidney disease (ADPKD) that, although rarely, can some-
539  an˜os  con  fallo  renal  y  calambre
Dear Editor,
Autosomal recessive polycystic kidney disease (ARPKD) is
a rare hereditary disease with an estimated incidence of
1:10,000 to 1:40,000.1,2 It is due to a mutation in the PKHD1
gene that codes for a protein called ﬁbrocystin or polyductin
which is responsible for differentiating between kidney and
bile duct tubules.1 It is characterised by kidney cysts with pro-
gressive kidney function deterioration and biliary dysgenesis
that causes congenital liver ﬁbrosis.2,3 Subtypes can be estab-
lished according to the age of presentation and severity of the
disease: prenatal, neonatal, childhood and young adult.3 The
most severe cases with nephromegaly and Potter’s syndrome
are described in the ﬁrst year of life,4 while those detected in
adolescence are less symptomatic and kidney function dete-
riorates later. Nevertheless, there are few published articles
describing patients that were diagnosed as adults.
A 39-year-old woman with no relevant medical history was
seen in the emergency room for cramping in her legs during
the last 6 months, but that had been more  severe during last
week. It was associated with asthenia, hyporexia, and 20 kg of
weight loss during the last year. She denied taking NSAIDs or
other drugs. No fever, photosensitivity, skin lesions, arthralgia,
or other symptoms of systemic disease. Physical examina-
tion was normal, except for a blood pressure of 93/61 mmHg.
The blood tests showed creatinine 5.53 mg/dl, urea 386 mg/dl,
sodium 127 mEq/l, potassium 5.3 mEq/l, magnesium 1.2 mg/dl,
calcium 6 mg/dl, PTH 672 pg/ml, haemoglobin 8.4 g/dl, pH 7.28,
bicarbonate 13.6 mmol/l, pCO2 29 mmol/l and anion GAP 19.
Urinalysis: proteinuria 310 mg/day, natriuria 186 mEq/day, cal-
ciuria 86 mg/day, magnesuria 48 mg/day, with no glycosuria,
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diagnosticada en mujer de 39 an˜os con fallo renal y calambres. Nefrolohaematuria, or leukocyturia. Anaemia and smear tests were
normal. Immunological and serum test were normal. The
TSH, cortisol, ACTH, and ADH hormones were normal, but
renin and aldosterone were elevated. Abdominal ultrasound:
kidneys decreased in size with poor corticomedullary differ-
entiation, cortex thinning, and predominant bilateral simple
medullary cysts under 1 cm,  with no lithiasis or hydronephro-
sis (Fig. 1). Cystic dilations of the intrahepatic bile ducts were
observed as an incidental ﬁnding on the ultrasound and con-
ﬁrmed with magnetic resonance cholangiopancreatography,
which are indicative of Caroli’s disease (Fig. 2).
After intravenous magnesium, calcium, potassium, and
bicarbonate treatment, the cramps resolved. She was pre-
scribed salt supplements to normalise her blood pressure. At
discharge: creatinine 4.5 mg/dl, sodium 133 mEq/l, potassium
3.7 mEq/l, calcium 7.1 mg/dl, magnesium 2.2 mg/dl, pH 7.34
and bicarbonate 24 mmol/l. Oral salt supplements were con-
sidered necessary. Family screening of her parents, siblings,
and children, with kidney ultrasound and blood tests was nor-
mal. There was no genetic relationship between her parents.
The conﬁrmatory diagnosis was obtained using genetic testing
that detected the mutation in the PKDH1 gene; furthermore,
the presence of associated tubulopathy was ruled out. After
four months, the patient began peritoneal dialysis.
ARPKD is a paediatric disease with kidney and liver symp-
toms, with few cases published of adult-onset. The differential
diagnosis was ﬁrst made as autosomal dominant polycysticC, Cabezuelo JB, García M. Poliquistosis renal autosómica recesiva
gia. 2016;36:318–320.
times be associated with Caroli’s disease. It was discarded
because her kidneys were not increased in size and the kid-
ney cysts were sub-centimetre in size. Other hereditary cystic
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Fig. 1 – Ultrasound (A) Cortical kidney sinus cysts. (B) Cystic dilation of the intrahepatic bile ducts.
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7Fig. 2 – Magnetic resonance cholangiopancreatography
ephropathies were also excluded: cystic medullary kidney
isease, nephronophthisis, disease caused by a mutation in
he HNF1b gene, tuberous sclerosis, Von Hippel-Lindau dis-
ase, as well as acquired cystic kidney disease: simple cysts,
cquired cystic disease, or Cacchi-Ricci disease.
In our case, the tubular changes, hypomagnesaemia, natri-
resis, and polyuria, with cramping symptoms were the
uiding symptoms. Although associated electrolyte changes
ave been described,6–8 this is the ﬁrst case of ARPKD in the
iterature that started with symptomatic hypomagnesaemia.
oreover, other concomitant tubulopathies, such as Gitelman
yndrome that could explain the ﬁndings of hyperrenin-
sm and hyperaldosteronism secondary to hypomagnesaemia,
ere ruled out by the genetic testing. In our patient, these
ould be due to the increased urinary excretion of sodium,
ater, and magnesium due to disfunctioning tubular cells.
There is a progressive deterioration of kidney function and
ore than half of the patients need renal replacement ther-
py before the age of 20 years.1,9 Hypertension is a factor of
oor prognosis, it starts during the ﬁrst months of life and
mproves with age.2,7 The patient did not present with a his-
ory of hypertension and during admission she had low blood
ressure, probably due to her salt-wasting nephropathy, which
ould have favoured the benign progression of this case.
In conclusion, ARPKD is a disease of the childhood, but
t should not forgotten that it can start in adults with
ore  moderate clinical manifestations. This disease should
e suspected in adults with end-stage chronic kidney dis-
ase, radiological ﬁndings that are compatible with the
iagnosis (millimetre medullary kidney cysts, dilation of the
8 Bilateral kidney cysts. (B) Caroli’s disease in the liver.
intrahepatic bile ducts), and associated symptomatic elec-
trolyte disorder.
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A  rare  cause  of diarrhea  in patients  with  focal  segmental
glomerulosclerosis
Una  causa  poco  frecuente  de  diarrea  en  pacientes  con
glomeruloesclerosis  focal  y  segmentaria
Dear Editor,
Focal segmental glomerulosclerosis (FSGS) symbolizes a com-
mon histologic pattern of glomerular injury associated with
numerous disease mechanisms. Ulcerative colitis (UC) repre-
sents one of the types of inﬂammatory bowel disease, which
occurs in genetically predisposed individuals. The coexistence
of these two diseases is an unexpected condition. Lately,
case reports have been published documenting the devel-
opment of nephropathy after treatment of ulcerative colitis
with mesalamine or sulphasalazine. In cases in the literature,
this coexistence has been identiﬁed as associated with 5-ASA
therapy.1–5 In this case, we report the ulcerative colitis occur-
ring in a patient with focal segmental glomerulosclerosis not
afﬁliated with 5-ASA therapy.
A 66-year-old man, with a 3-year history of focal segmen-
tal glomerulosclerosis, was admitted with bloody and mucoid
diarrhea which had been for lasting for 10 days. There was
no fever, nausea, vomiting or infection. There was no feature
in the patient’s history except diarrhea. Physical examina-
tion also was normal. Laboratory investigation demonstrated
impaired renal function and proteinuria due to focal segmen-
tal glomerulosclerosis. Renal function test which is similar to
the old values showed serum creatinine level of 3.15 mg/dl
(0.8–1.3), BUN level of 89 mg/dl (17–43) and 24-h urine pro-
tein level of 1876 mg/day (<200). In addition, his erythrocyte
sedimentation rate (ESR) was 79 mm/h  (<20) and C-reactive
protein (CRP) was 6.66 mg/dl (<0.4). A large amount of leuko-
cytes and erythrocytes was seen in the stool microscopy. Stool
cultures were detected negative twice. Colonoscopy revealed
that there were to exudates of millimetric ulcers descending
The patient was started on mesalamine. His symptoms
showed marked improvements after starting mesalamine
treatment. After treatment, laboratory investigation demon-
strated; creatinine level of 3.7 mg/dl (0.8–1.3), BUN level of
116 mg/dl (17–43), ESR level of 38 mm/h  (<20), CRP level of
0.319 mg/dl (<0.4), and 24-h urine protein level of 2099 mg/day
(<200). There were no abnormalities suggestive of nephro-
toxicity in patients due to mesalamine, while acute phase
reactants declined. The decline in ESR and CRP levels is
thought to be in favor of improving ulcerative colitis activation.
A focal segmental glomerulosclerosis after ulcerative col-
itis treatment with mesalamine and sulfasalazine has been
reported in the literature.1 Additionally in the literature,
there have been several minimal changes in the disease fol-
lowing the treatment of inﬂammatory bowel disease with
mesalamine or sulfasalazine.2–6 A case report has been pub-
lished of nephrotic syndrome due to Crohn’s disease with
mesalamine treatment.7
In this case, we discuss about the developed ulcerative
colitis in a patient who was followed for focal segmen-
tal glomerulosclerosis. Unlike previously reported cases,
mesalamine and sulfasalazine have no effect on the togeth-
erness of the two diseases. Although primary and secondary
FSGS forms are deﬁned based on the underlying cause, the
podocyte damage is a common result eventually. Some genetic
factors affect the inﬂammation which is the main cause of
development of the ulcerative colitis. An unknown cause such
as genetic, environmental or infections except drugs may be
factors in the etiology of these two diseases. Furthermore, an
unknown cause can facilitate the development of nephrotox-
icity after mesalamine and/or sulfasalazine treatment. In ourcolon, sigmoid colon and rectum. The colon biopsy conﬁrmed
the diagnosis of ulcerative colitis.case, the patient’s renal function did not change signiﬁcantly
after mesalamine treatment.
